Pharma / Biotech

Pharmacokinetics of faster and standard insulin aspart during fully closed-loop insulin delivery in type 2 diabetes.



Related Articles

Pharmacokinetics of faster and standard insulin aspart during fully closed-loop insulin delivery in type 2 diabetes.

Diabetes Technol Ther. 2020 Jan 30;:

Authors: Herzig D, Dehais J, Prost JC, Nakas CT, Stettler C, Bally L, Hovorka R

Abstract
Background Faster insulin aspart is a novel formulation of insulin aspart aiming to accelerate its subcutaneous absorption. The aim of the present study was to compare pharmacokinetics of faster insulin aspart versus standard insulin aspart in adults with type 2 diabetes during closed-loop insulin delivery. Methods We assessed the pharmacokinetics of faster (FA) and standard insulin aspart (A) from data obtained in a randomized double-blind crossover study evaluating fully closed-loop insulin delivery in adults with type 2 diabetes (n=13, age 59±10yrs, BMI 34.5±9.1kg/m2, HbA1c 7.7±1.2% [60±13mmol/mol]). Blood samples were collected every 15 to 30min over 10h to determine plasma insulin aspart concentration using liquid chromatography mass spectrometry. Time to peak plasma concentration (Tmax) was calculated using a two-compartment model, Results Tmax was 68.7±21.6min for FA and 89.7±31.8min for A (mean paired difference FA minus A -15.5min, 95% CI [-31.6; 0.6min], p=0.06). Metabolic clearance rate did not differ between the two insulins (p=0.61). Insulin amount delivered during closed-loop with FA positively correlated with Tmax (rS=0.73, p=0.01), whereas no statistically significant correlation was found with BMI, weight or HbA1C (all p>0.18). Conclusion In conclusion, Tmax tended to be shorter for FA vs A during fully automated closed-loop insulin delivery and correlated with the amount of insulin delivered.

PMID: 31999478 [PubMed – as supplied by publisher]

Source link




Related posts

Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study.

Newsemia

Anticoag Stewardship a Must for Complex Patients

Newsemia

Variety of Factors Affects Biosimilars Market Adoption

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy